mmk
jayanta
jncasracin
jh
bergenbio
jona
lie
vei
abstract
light
recent
outbreak
ebola
viru
ebov
diseas
west
africa
renew
effort
search
effect
antivir
countermeasur
rang
compound
current
avail
broad
antimicrobi
activ
test
activ
ebov
use
live
ebov
eighteen
candid
compound
screen
antivir
activ
vitro
compound
select
ration
basi
mechan
action
suggest
potenti
disrupt
ebov
entri
replic
exit
cell
display
antivir
activ
ebov
previou
test
nine
compound
caus
reduct
viral
replic
despit
cell
remain
healthi
exclud
analysi
zidovudin
didanosin
stavudin
abacavir
sulphat
entecavir
aimspro
celgosivir
castanospermin
second
screen
remain
compound
feasibl
appropri
vivo
test
remov
six
compound
ouabain
omeprazol
esomeprazol
gleevec
tasigna
three
promis
compound
screen
vivo
activ
guinea
pig
model
ebov
diseas
two
compound
show
effect
lethal
infect
vivo
concentr
test
warrant
investig
data
add
bodi
knowledg
antivir
activ
multipl
compound
ebov
indic
scientif
commun
invest
effort
develop
novel
specif
antivir
compound
treat
ebola
viru
diseas
ebolaviru
genu
famili
filovirida
includ
five
speci
bundibugyo
viru
bdbv
reston
viru
restv
sudan
viru
sudv
forest
viru
tafv
ebola
viru
ebov
ebola
viru
prototyp
speci
formal
design
zair
ebolaviru
respons
larg
outbreak
ebola
viru
diseas
evd
part
west
africa
first
recogn
decemb
ebov
virul
speci
famili
case
mortal
wherea
reston
speci
virtual
nonpathogen
human
respons
outbreak
west
africa
threat
outbreak
absenc
approv
proven
therapeut
vaccin
increas
intern
polit
humanitarian
scientif
momentum
identifi
treatment
strategi
context
ebov
outbreak
public
health
england
phe
approach
sever
academ
commerci
entiti
request
rapid
evalu
repurpos
drug
experiment
therapi
ebov
use
contain
level
facil
support
ebola
research
fund
initi
wellcom
trust
project
determin
viabl
drug
candid
develop
develop
eighteen
candid
report
select
sixti
credibl
lead
scientif
panel
cover
rang
potenti
promis
mechan
action
ebov
brief
detail
compound
nomin
inclus
outlin
ouabain
origin
use
treatment
heart
diseas
demonstr
reduc
ebov
replic
around
half
test
vitro
studi
look
viral
protein
protein
interrupt
cellular
interact
protein
inhibitor
heat
shock
protein
shown
reduc
vitro
ebov
replic
inhibitor
axl
receptor
tyrosin
kinas
appear
involv
ebola
viru
entri
host
cell
antibodi
therapi
target
integrin
propos
facilit
entri
filovirus
treatment
target
cell
clone
reduc
infect
use
vesicular
stomat
viru
vsiv
pseudotyp
ebov
glycoprotein
omeprazol
esomeprazol
magnesium
member
benzimidazol
may
stop
viral
entri
via
clathrinmedi
endocytosi
rais
endosom
ph
compound
shown
inhibit
lentivirusbas
pseudotyp
express
ebov
glycoprotein
gleevec
tasigna
market
name
imatinib
mesyl
nilotinib
respect
specif
tyrosin
kinas
inhibitor
origin
develop
anticanc
compound
propos
inhibit
phosphoryl
matrix
protein
requir
ebov
exit
cell
largescal
screen
antivir
ebov
group
identifi
gleevec
tasigna
potenti
ebov
inhibitor
aimspro
antiinflammatori
immunosuppress
drug
origin
develop
treatment
human
immunodefici
viru
hiv
product
hyperimmun
serum
goat
inject
inactiv
hiv
iiib
serum
reveal
presenc
rang
compon
includ
cytokin
interleukin
il
proopiomelanocortin
arginin
vasopressin
corticotropinreleas
factor
small
molecul
mimic
properti
antimicrobi
peptid
demonstr
potent
activ
drugresist
bacteria
biofilm
activ
class
compound
attribut
membran
disrupt
properti
peptid
mimic
sever
small
molecul
demonstr
activ
ebov
owe
membranedisrupt
wide
use
ebov
studi
compound
sourc
commerci
selleck
chemic
boston
usa
dalton
pharm
servic
toronto
canada
wherev
possibl
directli
supplier
readili
avail
bergenbio
bergen
norway
avipero
edinburgh
uk
aimspro
daval
intern
eastbourn
uk
synthes
character
jawaharl
nehru
centr
advanc
scientif
research
india
stock
solut
compound
made
doubl
final
dilut
take
account
equal
volum
viru
suspens
ad
sever
stock
suppli
dimethyl
sulfoxid
dmso
solut
dilut
highest
concentr
dmso
except
omeprazol
esomeprazol
highest
concentr
respect
within
laboratori
media
remov
inner
well
plate
due
edgeeffect
outer
well
left
media
ad
compound
ad
five
replic
per
dilut
three
viru
addit
two
mockinfect
first
vitro
screen
ebov
suspens
strain
recent
renam
ad
tcid
tissu
cultur
infecti
dose
percent
concentr
approxim
triplic
well
per
compound
dilut
remain
two
well
media
alon
ad
base
inhibit
ebovinduc
cytopath
effect
differ
cell
line
supernat
cell
harvest
day
postinfect
respect
cell
microscop
assess
condit
monolay
viral
replic
measur
compar
seri
time
point
use
realtim
polymeras
chain
reaction
pcr
approach
one
hundr
forti
microlit
supernat
ad
avl
buffer
rna
extract
sealabl
deep
plate
remov
laboratori
extract
rna
perform
use
magnapur
small
volum
rna
kit
roch
burgess
hill
uk
magnet
beadbas
method
rna
separ
brief
sampl
vessel
transfer
magnapur
plate
prior
load
onto
magnapur
autom
extract
robot
rna
elut
nucleasefre
water
target
amplif
perform
use
primer
zair
ebolaviru
glycoprotein
describ
trombley
et
al
use
fast
viru
qrtpcr
kit
qiagen
manchest
uk
analysi
perform
use
abi
appli
biosystem
paisley
uk
follow
cycl
condit
c
min
c
follow
cycl
c
c
temperatur
cycl
set
maximum
ramp
speed
data
acquir
analyz
use
abi
onboard
softwar
version
appli
biosystem
paisley
uk
threshold
set
cycl
threshold
ct
valu
pcr
assay
use
give
consist
read
amount
ebov
rna
level
sampl
six
compound
interest
assess
toxic
base
avail
result
first
vitro
screen
avail
ie
omeprazol
esomeprazol
ouabain
gleevec
serial
dilut
made
incub
cell
three
day
incub
cell
visual
assess
cytotox
monolay
fix
formaldehyd
solut
stain
crystal
violet
gross
visual
inspect
cell
attach
screen
assay
repeat
assess
effect
ebov
use
cell
follow
chang
previou
method
employ
compound
test
dilut
shown
exert
cytotox
effect
uninfect
cell
ii
higher
viral
inoculum
use
approxim
tcid
well
iii
sampl
harvest
two
day
guinea
pig
use
efficaci
studi
use
group
size
n
anim
studi
perform
condit
procedur
undertaken
accord
unit
kingdom
anim
scientif
procedur
act
studi
approv
phe
ethic
committe
project
licenc
approv
uk
home
offic
inspector
vascular
cathet
insert
prior
arriv
allow
safe
access
intraven
rout
deliveri
anim
challeng
via
subcutan
rout
dose
tcid
guinea
pigadapt
ebov
passag
five
time
vivo
challeng
prepar
back
titrat
cell
confirm
dose
h
postchalleng
treatment
initi
compound
dissolv
ww
hydroxypropyl
ww
give
concentr
equat
mgkg
ml
dose
ml
given
oral
twice
daili
compound
dilut
steril
water
give
concentr
equat
mgkg
one
millilit
deliv
via
intraven
iv
rout
twice
daili
suppli
commerci
selleck
product
dissolv
dmso
give
concentr
equat
mgkg
ml
dose
deliv
intraperiton
ip
schedul
everi
day
neg
control
group
consist
guinea
pig
ebov
challeng
receiv
treatment
day
anim
individu
weigh
temperatur
record
subcutaneouslyinsert
temperatureidentif
id
chip
prevent
unnecessari
anim
suffer
human
clinic
endpoint
use
standard
anim
would
cull
use
uk
home
offic
approv
schedul
method
endpoint
consist
weight
loss
moder
clinic
symptom
eg
lethargi
etc
b
weight
loss
c
show
sign
distress
determin
consult
name
anim
care
welfar
offic
due
larg
number
compound
sixti
initi
propos
antivir
test
score
assess
undertaken
triag
compound
relat
capac
avail
test
assess
base
technic
readi
level
trl
tabl
adapt
unit
state
depart
defens
avail
previou
evid
efficaci
ebov
tabl
addit
compani
institut
suggest
compound
ask
score
drug
provid
justif
inform
togeth
inform
publiclyavail
literatur
time
scientif
panel
identifi
eighteen
compound
suitabl
screen
tabl
recommend
use
concentr
compound
sought
supplier
andor
inform
public
domain
use
concentr
level
ebov
rna
infect
two
cell
line
assess
give
readout
viral
replic
addit
viral
rna
level
cytopath
effect
cpe
assess
toxic
effect
tabl
result
identifi
nine
compound
reduct
viral
replic
despit
cell
remain
healthi
zidovudin
didanosin
stavudin
abacavir
sulphat
entecavir
aimspro
celgosivir
castanospermin
remov
evalu
sever
compound
show
reduct
viral
rna
level
drug
ouabain
omeprazol
esomeprazol
magnesium
gleevec
tasigna
also
exhibit
signific
cpe
cell
monolay
howev
three
compound
gave
reduct
ct
valu
cell
remain
attach
albeit
latter
two
compound
affect
morpholog
cell
extent
repeat
screen
assay
compound
show
antiebov
activ
conduct
use
cell
initi
screen
similar
respons
observ
cell
higher
concentr
viru
inoculum
incub
two
day
addit
compound
previous
test
recommend
concentr
exert
cytotox
effect
concentr
use
adjust
determin
optimum
concentr
caus
toler
toxic
incub
uninfect
cell
two
day
result
experi
confirm
vitro
antivir
activ
ebov
compound
test
tabl
three
compound
demonstr
vitro
activ
ebov
screen
effect
ebov
diseas
guinea
pig
model
compound
chosen
caus
highest
level
viral
rna
reduct
repres
differ
mode
activ
suitabl
use
current
vivo
model
without
modif
chang
ethic
licens
test
ebovinfect
guinea
pig
deliv
oral
two
dose
per
day
start
h
postchalleng
result
show
treatment
fail
exert
statisticallysignific
protect
effect
compar
untreat
anim
n
per
group
p
logrank
surviv
analysi
figur
weight
temperatur
differ
postebov
challeng
show
anim
met
human
clinic
endpoint
exhibit
weight
loss
anim
rise
temperatur
figur
c
howev
weight
loss
observ
one
anim
group
surviv
day
postchalleng
schedul
end
studi
indic
anim
exert
protect
effect
deliv
oral
two
dose
per
day
start
h
postchalleng
result
show
treatment
fail
exert
statisticallysignific
protect
effect
compar
untreat
anim
n
per
group
p
logrank
surviv
analysi
figur
weight
temperatur
differ
postebov
challeng
show
anim
met
human
clinic
endpoint
exhibit
weight
loss
anim
rise
temperatur
figur
c
howev
weight
loss
observ
one
anim
group
surviv
day
postchalleng
schedul
end
studi
indic
anim
exert
protect
effect
although
increas
time
death
observ
statist
signific
n
per
group
p
logrank
surviv
analysi
figur
anim
exhibit
weight
loss
rise
temperatur
figur
c
anim
group
began
increas
weight
nine
day
postchalleng
indic
recoveri
ebov
infect
anim
surviv
schedul
end
studi
deliv
intraven
two
dose
per
day
start
h
postchalleng
although
increas
time
death
observ
statist
signific
n
per
group
p
logrank
surviv
analysi
figur
anim
exhibit
weight
loss
rise
temperatur
figur
c
anim
group
began
increas
weight
nine
day
postchalleng
indic
recoveri
ebov
infect
anim
surviv
schedul
end
studi
schedul
deliv
via
intraperiton
rout
everi
two
day
howev
treat
anim
met
human
endpoint
within
h
deliveri
first
dose
therefor
effect
compound
ebov
could
ascertain
experi
recent
outbreak
ebov
diseas
west
africa
highlight
urgent
need
therapeut
need
might
met
quickli
effici
exist
drug
known
safeti
profil
could
repurpos
treat
ebov
effect
studi
screen
eighteen
theoreticallypromis
antivir
therapi
ebov
use
vitro
vivo
experi
live
viru
given
serious
long
run
extent
west
african
evd
outbreak
develop
experiment
workflow
rapidli
screen
compound
antivir
activ
order
focu
effort
resourc
promis
therapi
first
vitro
screen
use
multipl
infect
moi
approxim
half
compound
fail
show
activ
compound
exclud
studi
second
screen
use
moi
approxim
eight
remain
nine
compound
continu
schedul
deliv
via
intraperiton
rout
everi
two
day
howev
treat
anim
met
human
endpoint
within
h
deliveri
first
dose
therefor
effect
compound
ebov
could
ascertain
experi
recent
outbreak
ebov
diseas
west
africa
highlight
urgent
need
therapeut
need
might
met
quickli
effici
exist
drug
known
safeti
profil
could
repurpos
treat
ebov
effect
studi
screen
eighteen
theoreticallypromis
antivir
therapi
ebov
use
vitro
vivo
experi
live
viru
given
serious
long
run
extent
west
african
evd
outbreak
develop
experiment
workflow
rapidli
screen
compound
antivir
activ
order
focu
effort
resourc
promis
therapi
first
vitro
screen
use
tcid
well
multipl
infect
moi
approxim
half
compound
fail
show
activ
compound
exclud
studi
second
screen
use
tcid
well
moi
approxim
eight
remain
nine
compound
continu
demonstr
mean
reduct
viral
replic
screen
drug
tasigna
retest
due
compound
unavail
addit
drug
gleevec
includ
sinc
report
oper
via
mechan
demonstr
better
vitro
efficaci
vitro
screen
use
viral
rna
level
readout
base
previou
antivir
test
work
infecti
dose
moi
similar
level
use
antiebov
test
studi
given
compound
test
studi
chosen
due
perceiv
potenti
effect
use
ebov
neg
result
demonstr
import
test
therapi
use
actual
live
pathogen
determin
effect
also
highlight
uncertainti
inher
extrapol
mechan
action
data
drug
repurpos
matter
ration
eight
compound
show
repeat
antivir
activ
ebov
vitro
three
select
vivo
studi
use
guinea
pig
model
infect
ie
wherea
omeprazol
esomeprazol
demonstr
vitro
activ
ebov
result
line
previou
report
use
pseudotyp
virus
valu
drug
concentr
caus
inhibit
ic
region
suggest
dose
requir
potent
inhibit
would
difficult
achiev
without
concomit
signific
toxic
licenc
dose
mg
esomeprazol
mg
esomeprazol
mg
omeprazol
gener
median
maximum
plasma
concentr
respect
gleevec
brand
name
imatinib
mesyl
follow
vivo
test
sinc
optim
dose
requir
ie
continu
dose
feasibl
current
setup
anim
model
requir
continu
dose
due
short
halflif
rat
similar
compound
addit
plasma
concentr
gleevec
usual
reach
normal
dosag
other
suggest
concentr
effect
ebov
inhibit
would
possibl
howev
data
vitro
studi
live
ebov
report
show
effect
even
use
membraneact
small
molecul
mimic
properti
natur
antimicrobi
peptid
may
neg
impact
viral
envelop
cellular
lipid
bilay
two
molecul
less
activ
henc
efficaci
assess
anim
model
guinea
pig
model
ebov
diseas
use
work
sinc
present
robust
access
broadli
reflect
rodent
model
screen
countermeasur
importantli
model
also
allow
catheter
anim
use
allow
direct
access
intraven
rout
prefer
rout
deliveri
mani
antivir
compound
compat
work
highest
microbiolog
contain
posit
effect
ebov
infect
guinea
pig
observ
relat
surviv
untreat
control
exhibit
mortal
howev
survivor
group
show
signific
loss
weight
typic
ebovinfect
guinea
pig
exhibit
survivor
untreat
group
surviv
guinea
pig
exhibit
increas
temperatur
typic
ebov
infect
model
possibl
observ
consequ
broad
guinea
pig
respons
sinc
anim
outbr
individu
subtl
differ
respons
effect
propos
due
inhibit
tyrosin
kinas
inhibitor
thu
could
specul
tyrosin
kinas
inhibitor
includ
two
studi
gleevec
tasigna
would
also
demonstr
protect
effect
treatment
ebovchalleng
guinea
pig
instanc
show
effect
diseas
progress
demonstr
increas
mean
time
death
albeit
statist
signific
anim
treat
exhibit
weight
loss
temperatur
increas
line
level
untreat
anim
interestingli
class
compound
test
bacteri
pathogen
found
quit
effect
peptid
mimic
demonstr
antivir
activ
ebov
well
howev
note
although
show
high
level
antivir
activ
cell
monolay
phenotyp
differ
cell
line
observ
warrant
investig
especi
depend
activ
concentr
compound
nevertheless
welltoler
test
guinea
pig
led
recoveri
one
anim
ebov
infect
test
guinea
pig
effect
could
clearli
ascertain
sinc
anim
met
human
endpoint
prior
diseas
symptom
ebov
diseas
dose
use
studi
mgkg
wherea
report
use
guinea
pig
other
shown
mgkg
deliv
oral
well
toler
mice
rat
therefor
like
noncompat
interact
compon
guinea
pig
physiolog
result
toxic
effect
test
effect
ebov
anim
system
compound
shown
nontox
use
mous
howev
due
mous
model
relev
human
diseas
guinea
pig
valu
conduct
studi
may
counterproduct
summari
result
provid
detail
antivir
properti
eighteen
potenti
therapi
wherea
experi
limit
could
extend
includ
viabl
viral
load
plaqu
assay
modern
method
assess
cytotox
studi
conduct
provid
rapid
result
activ
ebov
outbreak
within
limit
facil
handl
live
ebov
within
special
cabinetlin
system
candid
studi
chosen
via
projectspecif
select
committe
compris
member
phe
academia
wellcom
trust
screen
approach
larg
number
compound
select
base
perceiv
activ
ebov
howev
valu
work
use
live
ebov
provid
valuabl
insight
compound
warrant
investig
import
show
antivir
effect
ebov
conclus
data
report
help
inform
decis
compound
investig
equal
importantli
one
given
limit
facil
restrict
work
live
hazard
group
virus
focu
treatment
shown
promis
live
ebov
use
vitro
vivo
model
intens
intellectu
focu
problem
gener
scientif
paper
studi
review
gener
research
idea
hypothes
experiment
design
address
relat
scientif
issu
hypothesi
es
gener
research
plan
andor
protocol
develop
peer
review
approv
focus
literatur
review
conduct
scientif
discuss
held
gener
research
plan
studi
identifi
potenti
target
opportun
therapeut
intervent
facilit
strateg
plan
support
analys
provid
scientif
inform
data
develop
research
propos
fill
data
gap
identifi
candid
concept
andor
therapeut
drug
document
peerreview
approv
protocol
research
plan
basic
research
data
collect
analysi
begin
order
test
hypothesi
explor
altern
concept
identifi
evalu
critic
technolog
compon
support
research
eventu
develop
pharmaceut
candid
identif
site
mechan
action
potenti
correl
protect
vaccin
well
initi
character
candid
initi
proofofconcept
candid
construct
demonstr
limit
number
vitro
vivo
research
model
document
result
laboratori
studi
demonstr
preliminari
proofofconcept
candid
construct
vitro
anim
studi
nongood
laboratori
practic
glp
research
refin
hypothesi
identifi
relev
parametr
data
requir
technolog
assess
rigor
worst
case
experiment
design
exploratori
studi
candid
drug
critic
technolog
effect
integr
candid
biologicvaccin
construct
candid
drug
biologicsvaccin
evalu
anim
model
identifi
assess
safeti
toxic
adversebiologicalsid
effect
assay
andor
surrog
marker
endpoint
use
nonclin
clinic
studi
evalu
character
candid
pharmaceut
identifi
proofofconcept
safeti
candid
drug
formul
candid
biologicvaccin
construct
demonstr
defin
laboratoryanim
model
document
proofofconcept
safeti
candid
demonstr
result
formul
studi
propos
productionpurif
method
biologicvaccin
laboratori
test
pharmacokinet
studi
select
laboratoryanim
model
implement
expand
phase
clinic
trial
surrog
test
gather
inform
rel
safeti
effect
candid
drugbiologicvaccin
trial
conduct
evalu
overal
riskbenefit
administ
candid
product
provid
adequ
basi
label
process
valid
complet
follow
lot
consistencyreproduc
studi
case
drug
new
drug
applic
nda
submit
cder
follow
prenda
meet
type
b
case
biologicvaccin
biolog
licens
applic
bla
prepar
submit
cber
follow
prebla
meet
type
b
facil
preapprov
inspect
pai
complet
approv
nda
drug
cder
approv
bla
biologicsvaccin
cber
fda
issuanc
approv
letter
review
nda
bla
applic
submit
sponsor
pharmaceut
document
criterion
pharmaceut
ie
drugbiologicvaccin
distributedmarket
postmarket
studi
nonclin
clinic
may
requir
design
agreement
fda
postmarket
surveil
none
continu
surveil
fda
transmit
requir
postmarket
studi
begin
postapprov
report
requir
maintain
cgmp
complianc
document
prove
candid
pharmaceut
licens
wellregul
eg
fda
medicin
healthcar
product
regulatori
agenc
mhra
market
requir
develop
wide
avail
score
use
approv
use
clinic
trial
patient
eg
emerg
use
author
expand
access
compassion
use
guarante
avail
score
suppli
outlin
decis
criterion
reliabl
estim
feasibl
cost
timelin
etc
score
thu
levelqu
exist
data
packag
licensureind
human
commitmenttrack
record
develop
feasibl
suppli
suffici
dose
studi
subsequ
solv
current
epidem
welldocu
like
efficaci
pathogen
microorgan
interest
prior
efficaci
data
pathogen
microorgan
relat
agent
interest
exampl
reduct
load
hostimmun
respons
scientif
studi
report
commercialinconfid
inform
document
evid
eg
theoret
silico
vitro
andor
vivo
data
candid
like
efficaci
pathogen
microorgan
relat
agent
interest
suggest
score
silico
vitro
vivo
practic
costeffect
tiebreak
practic
costeffect
solut
frontlin
clinic
respons
current
well
futur
epidem
document
prove
current
like
formul
complex
eg
oral
intraven
iv
multipl
dose
transit
exist
gold
standard
treatment
would
difficult
candid
would
could
costeffect
solut
especi
make
differ
patient
affect
current
epidem
